Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Document Type

Article

Publication Date

1-1-2022

Publication Title

Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

Keywords

washington; swedish; seattle

Clinical Institute

Cancer

Department

Oncology

Department

Hematology

Share

COinS